Biogen, Inc. (BIIB)
$293.68 0.43 (0.15%)
14:18 EST BIIB Stock Quote Delayed 15 Minutes
Previous Close $293.25
Market Cap 61.97B
PE Ratio 20.98
Volume (Avg. Vol.) 621,694
Day's Range 290.52 - 294.92
52-Week Range 215.77 - 344.00
Dividend & Yield N/A (N/A)
BIIB Stock Predictions, Articles, and Biogen, Inc. News
- From InvestorPlace
- From the Web
With news that Biogen’s Alzheimer’s drug was allowed to reapply for possible FDA approval, Biogen stock skyrocketed. However, investors will want to carefully consider all angles before jumping onboard.
This morning, I'm recommending a bullish call option on Aimmune Therapeutics, Inc. (NASDAQ:AIMT), the biopharmaceutical company.
Options trading was buzzing in Biogen, McDonald's and Lyft stock on Tuesday. Here are the metrics that matter moving forward.
Biogen erupted in early trading, as it seeks approval for its Alzheimer's treatment. Here's what happened in the stock market today.
Healthcare in particular is one such sector, with a number of large-cap biotechnology and pharmaceutical stocks enjoying fresh rallies.
Another opioid settlement has been reached and earnings season is heating up. Here's what happened in the stock market today.
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).
Biogen earnings for the second quarter of the year have BIIB stock heading higher on Tuesday thanks to a strong EPS and revenue beat.
The owners of Biogen stock will examine Biogen earnings to asss the progress that BIIB is making in key areas, including Ms and Spinraza.
The second quarter is the books, at least as far as the stock market is concerned. Here's a look at the Nasdaq today.
PayPal, Slack, and chip stocks like AMD and Nvidia, Micron and Nio were all big movers in the Nasdaq today. Get the scoop, now.
If you’re looking for the next big thing in investing, these three down but not out biotech stocks are the way to go.
Zynerba landed a new patent for its Zygel product to use cannabidiol as a treatment for Autism Spectrum Disorder, sending ZYNE stock ripping.
Smaller-capitalization biotechs can be riskier investments, but EXEL stock has more than just promise off and on the price chart and is readying to be purchased.
Biogen stock is under big-time pressure, with BIIB falling more than 30% over the past two trading sessions. Is the coast clear yet?
From Talk Markets
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!